NIKI BIOSOLUTIONS INC
NIKINASDAQTrading Snapshot
- Day Range
- $1.78 – $2.09
- 52-Week Range
- $1.78 – $172.00
- Volume (shares)
- 5,366
- Avg Volume (shares)
- —
- Shares Outstanding
- 81,436
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-18.54
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +16.9%
NIKI BIOSOLUTIONS INC
NIKI
StockOtter · stockotter.spaceAbout NIKI BIOSOLUTIONS INC
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer's clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NA
Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series
Company's blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome
Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer's biomarker cohort PRINCETON, N.J., and NEW HAVEN, Conn.
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomark
Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics
Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform